Vulvovaginal atrophy: a widespread but underestimated problem
Vulvovaginal atrophy (VVA) is a chronic and progressive condition that affects approximately 50-70% of post-menopausal women and also a significant percentage of women who experience reduced estrogen levels due to cancer or other medical therapies. According to North American Menopause Society (NAMS) VVA symptoms can deeply impact quality of life, affecting vulvovaginal well-being, sexuality and even urinary health.
Symptoms related to Vulvovaginal atrophy
The main signs and symptoms of VVA include:
- Vaginal dryness (manifested by 50-83% of post-menopausal women)
- Dyspareunia (pain during intercourse, affecting between 38% and 59% of women)
- Burning and itching
- Recurrent vaginitis and urinary infections
For women affected by breast cancer undergoing Tamoxifen therapy, these symptoms are often more intense, as hormonal cancer treatments enhance estrogen deficiency. This has an even greater impact on quality of life, often leading patients to avoid sexual intercourse and experience persistent discomfort.
Treatment options for Vulvovaginal atrophy
Most common treatments for VVA include:
- Local hormone therapies (creams, oestrogen-based ova)
- Vaginal lubricants and moisturisers
- Non-hormonal technologies such as radiofrequency and electroporation
Among these, the combined use of radiofrequency and electroporation is becoming an effective, safe and non-invasive solution for the improvement of intimate well-being without resorting to hormonal treatments.
The Study of Dr. Stefano Berardi on Vagy combi
Dr. Stefano Berardi conducted a study on patients affected by VVA who underwent a Tamoxifen therapy for breast cancer. The main purpose of the study is to evaluate the efficacy of radiofrequency combined with electroporation.
Treatment protocol
Patients were treated with Vagy Combi, an innovative device from Top Quality Group that uses the synergy of radiofrequency and electroporation to improve vaginal tissue hydration and tropism.
- Treatment time: 7 weeks
- Attendance: 1 session per week
- Each session includes:
- 10 minutes of radiofrequency
- 10 minutes of electroporation
Delivered active principle: 2% hyaluronic acid solution (cream or gel)
Study results
Six months after the end of the treatment the results show:
✅ Reduction of vaginal dryness and pain during intercourse
✅ Improvement of patients’ quality of life
✅ Resumption of sexual activity without dyspareunia
✅ No side effects detected
Although some patients reported a slight return of symptoms after 6 months, the benefits of treatment were preserved, with a significant reduction in discomfort compared to the pre-treatment period.
Why choose Vagy Combi to treat vulvovaginal atrophy?
Vagy Combi is a cutting-edge device that offers a non-invasive, hormone-free solution for the treatment of vulvovaginal atrophy. Thanks to the combination of radiofrequency and electroporation, it promotes/supports:
✔ Regeneration of vaginal tissue
✔ Improvement of elasticity and hydration
✔ Reduction of symptoms of VVA